ArticleDiabetology & metabolic syndrome2024
INFLA score: a novel inflammatory marker for assessing cardiometabolic disease risk in obese individuals.
Article in Diabetology & metabolic syndrome, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic and prognostic value of systemic immune-inflammation index for heart failure: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2025Pooled it
- Protective Effects of Apolipoprotein A and High-Density Lipoprotein Cholesterol Against Interstitial Lung Disease in Rheumatoid Arthritis: The Mediating Role of Systemic Inflammation.Rheumatology and therapy · 2026Article
- Interaction and Joint Effects of Inflammation and Triglyceride-Glucose (TyG) Index on Hyperuricemia Risk and the Mediating Role of TyG: A Cross-Sectional Study.Endocrinology, diabetes & metabolism · 2026Article
- MIND-NL diet adherence moderates the relation of low-grade systemic inflammation with neuroinflammatory metabolites and cognitive functioning: an exploratory cross-sectional study in older adults.Journal of neuroinflammation · 2026Article
- Associations between oral health problems and inflammatory bowel disease: evidence from prospective cohort study.Frontiers in immunology · 2026Article
- Predicting susceptibility to inflammaging using a genetic inflammatory index through Prakriti-based phenotypic stratification.Frontiers in immunology · 2026Article
- Low-grade inflammation score (INFLA- score) associated with metabolic syndrome and its components in shift workers.Diabetology & metabolic syndrome · 2025Article
- Poor sleep health is associated with older brain age: the role of systemic inflammation.EBioMedicine · 2025Article
- Association of Android and Gynoid Fatness With Incident Dementia and Brain Structure.Journal of cachexia, sarcopenia and muscle · 2025Article
- Association between relative muscle strength and cardiometabolic multimorbidity in middle-aged and older Chinese adults.Acta diabetologica · 2025Article
- Chronic low-grade inflammation associated with higher risk and earlier onset of cardiometabolic multimorbidity in middle-aged and older adults: a population-based cohort study.Scientific reports · 2024Article
- Mechanisms of inflammatory microenvironment formation in cardiometabolic diseases: molecular and cellular perspectives.Frontiers in cardiovascular medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe low-grade inflammation score (INFLA-score) is a composite index that assesses chronic inflammatory status using multiple inflammatory markers. However, its correlation with cardiometabolic diseases (CMDs) in obese populations remains unclear.
methodsWe conducted a prospective cohort study involving 79,160 participants with obesity (BMI ≥ 30 kg/m
resultsOver a median follow-up of 161.41 months, we recorded 14,903 CMDs events, comprising 7184 CAD cases, 1914 strokes and 7924 T2DM cases. Cox regression analysis revealed that each unit increase in the INFLA-score corresponded to a 1.5%, 1.1%, 1.2% and 2.4% increase CMDs risk (HR: 1.015, 95% CI 1.013-1.018), CAD risk (HR: 1.011, 95% CI 1.007-1.015), stroke risk (HR: 1.012, 95% CI 1.004-1.020) and T2DM risk (HR: 1.024, 95% CI 1.020-1.028), respectively. Restricted cubic spline analysis indicated a non-linear relationship between cumulative INFLA-score and CMDs risk (P = 0.044). Subgroup analysis revealed interactions between sex, age, history of lipid-lowering drug use, and INFLA-score regarding CMDs risk. Sensitivity analysis corroborated the main findings.
conclusionOur findings strongly support the close association between INFLA-score and CMDs risk, particularly notable in women, those aged < 55, and individuals with a history of lipid-lowering drug use. These findings offer new insights into the role of inflammation in obesity-related CMDs, suggesting potential applications for prevention and identification of high-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.